A study testing whether a GLP-1 medicine, semaglutide, can help people with HIV drink less.

Recruiting now. Registry record last updated March 24, 2026.

Who can join: Adults 18 to 99, have alcohol use disorder, BMI 23+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 17 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Yale UniversityDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 30

What this study is for

Primary condition: Alcohol Use Disorder (AUD). Also studied in: HIV.

Full scientific study title: Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide.

Who can join

Age18 to 99SexAnyBMI23 or higher

Adults 18 to 99, have alcohol use disorder, BMI 23+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

diagnosed with HIV
Receive care at the Atlanta VA Healthcare System
Age 18 or over
Meet criteria for mild, moderate, or severe alcohol use disorder by the DSM-5 Alcohol Symptom Checklist and the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) screen
Have evidence of significant alcohol use: PEth \> 20ng/ml

Key exclusion criteria

Active engagement in formal alcohol treatment including medications for alcohol use disorder at the time of enrollment
Self-report or laboratory test confirming pregnancy, nursing, or trying to conceive
Life-threatening or unstable medical, surgical, or psychiatric condition that prohibits participation (including current or past intent to harm oneself or others within the prior 12 months and not receiving treatment)
Untreated moderate to severe opioid use disorder
Residence out of state

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Georgia1 site

Atlanta VA Medical Center
Decatur, Georgia
Ketteria Ingram407-914-6083Ketteria.Ingram@va.gov

Follow this trial

We email you if NCT07040592 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: January 15, 2026. Expected completion: June 30, 2027. Last updated on ClinicalTrials.gov: March 24, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.